Christian M Meerwein1,2, Martin Hüllner3,4, Ralph Braun5,4, Michael B Soyka6,4, Grégoire B Morand6,4, David Holzmann6,4. 1. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland. christian.meerwein@usz.ch. 2. University of Zurich, Zurich, Switzerland. christian.meerwein@usz.ch. 3. Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland. 4. University of Zurich, Zurich, Switzerland. 5. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. 6. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Abstract
PURPOSE: To present outcome measures of sinonasal mucosal melanoma (SMM) patients with particular focus on current radiological and therapeutic options, especially in the non-curative setting (immunotherapy). METHODS: Retrospective study on SMM patients treated at our institution between January 1992 and December 2018. RESULTS: FDG-PET/MRI has emerged as the new hybrid imaging modality, addressing the need for high local tissue contrast in the paranasal sinuses and the skull base, while allowing for whole-body staging in search for distant metastases, including the brain. Primary treatment protocols consisted of tumor resection in 30/34 patients (88%), palliative radiation therapy (RT) in 3/34 patients (9%) and best supportive care therapy in 1/34 patient (3%). Of all the initially operated patients, 25/30 patients (83%) received adjuvant RT. A total of 9/34 patients (26%) was treated with immunotherapy after the previous combined therapy. For patients treated in curative intention, we observed a 1-year overall survival (OS) of 60% (18/30 patients) and a 3-year OS of 40% (12/30 patients). For patients treated with immunotherapy, median progression-free survival (PFS) was 5 months (IQR 0-13.75), with a maximum PFS of 16 months (combination of nivolumab and ipilimumab). However, there was no difference in OS in patients treated with immunotherapy vs. no immunotherapy (log rank 0.99). CONCLUSIONS: Sinonasal mucosal melanoma is a highly aggressive tumor, requiring multimodal therapy and developing a substantial incidence of distant metastases. The introduction of FDG-PET/MRI offers new possibilities in the radiological assessment of the tumor and immunotherapy has altered the management in the non-curative setting, resulting in a substantial progression-free survival in selected cases.
PURPOSE: To present outcome measures of sinonasal mucosal melanoma (SMM) patients with particular focus on current radiological and therapeutic options, especially in the non-curative setting (immunotherapy). METHODS: Retrospective study on SMM patients treated at our institution between January 1992 and December 2018. RESULTS: FDG-PET/MRI has emerged as the new hybrid imaging modality, addressing the need for high local tissue contrast in the paranasal sinuses and the skull base, while allowing for whole-body staging in search for distant metastases, including the brain. Primary treatment protocols consisted of tumor resection in 30/34 patients (88%), palliative radiation therapy (RT) in 3/34 patients (9%) and best supportive care therapy in 1/34 patient (3%). Of all the initially operated patients, 25/30 patients (83%) received adjuvant RT. A total of 9/34 patients (26%) was treated with immunotherapy after the previous combined therapy. For patients treated in curative intention, we observed a 1-year overall survival (OS) of 60% (18/30 patients) and a 3-year OS of 40% (12/30 patients). For patients treated with immunotherapy, median progression-free survival (PFS) was 5 months (IQR 0-13.75), with a maximum PFS of 16 months (combination of nivolumab and ipilimumab). However, there was no difference in OS in patients treated with immunotherapy vs. no immunotherapy (log rank 0.99). CONCLUSIONS:Sinonasal mucosal melanoma is a highly aggressive tumor, requiring multimodal therapy and developing a substantial incidence of distant metastases. The introduction of FDG-PET/MRI offers new possibilities in the radiological assessment of the tumor and immunotherapy has altered the management in the non-curative setting, resulting in a substantial progression-free survival in selected cases.
Authors: John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz Journal: JAMA Date: 2011-06-08 Impact factor: 56.272
Authors: Bin Lian; Lu Si; Chuanliang Cui; Zhihong Chi; Xinan Sheng; Lili Mao; Siming Li; Yan Kong; Bixia Tang; Jun Guo Journal: Clin Cancer Res Date: 2013-07-05 Impact factor: 12.531
Authors: Simon J Furney; Samra Turajlic; Gordon Stamp; Mahrokh Nohadani; Anna Carlisle; J Meirion Thomas; Andrew Hayes; Dirk Strauss; Martin Gore; Joost van den Oord; James Larkin; Richard Marais Journal: J Pathol Date: 2013-07 Impact factor: 7.996
Authors: Christian Buchbender; Till A Heusner; Thomas C Lauenstein; Andreas Bockisch; Gerald Antoch Journal: J Nucl Med Date: 2012-07-10 Impact factor: 10.057
Authors: William M Mendenhall; Robert J Amdur; Russell W Hinerman; John W Werning; Douglas B Villaret; Nancy Price Mendenhall Journal: Am J Clin Oncol Date: 2005-12 Impact factor: 2.339
Authors: O Stanimirov Rossi; Domenic Vital; M B Soyka; T N Roth; G F Huber; D Holzmann Journal: Eur Arch Otorhinolaryngol Date: 2014-05-29 Impact factor: 2.503
Authors: Alexander Maurer; Christian M Meerwein; Michael B Soyka; Hannes Grünig; Stephan Skawran; Urs J Mühlematter; Michael Messerli; Cäcilia E Mader; Lars Husmann; Niels J Rupp; David Holzmann; Martin W Huellner Journal: Head Neck Date: 2021-09-13 Impact factor: 3.821